Kaposi sarcoma following dupilumab treatment for bullous pemphigoid: A case report and review of literature

doi:10.12998/wjcc.v14.i15.120825

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 15

This Article

(32)

(23)

(0)

(11)

(482)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Cases. May 26, 2026; 14(15): 120825
Published online May 26, 2026. doi: 10.12998/wjcc.v14.i15.120825

Full Size Figure Download Figure

Figure 1 Clinical presentation of Kaposi sarcoma lesions after 32 weeks of treatment. A-C: Multiple violaceous-red papules on both feet after 32 weeks of treatment.

Citation: Wang SN, Wang JM, Xu M, Wu JJ. Kaposi sarcoma following dupilumab treatment for bullous pemphigoid: A case report and review of literature. World J Clin Cases 2026; 14(15): 120825
URL: https://www.wjgnet.com/2307-8960/full/v14/i15/120825.htm
DOI: https://dx.doi.org/10.12998/wjcc.v14.i15.120825

Wang SN, Wang JM, Xu M, Wu JJ. Kaposi sarcoma following dupilumab treatment for bullous pemphigoid: A case report and review of literature. World J Clin Cases 2026; 14(15): 120825 [DOI: 10.12998/wjcc.v14.i15.120825]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.